• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconAllergan

Allergan

Page 3 of 6
White tablets
HealthTeva Says Its Deal to Buy Allergan’s Generics Business Will Close ‘Any Time’
By ReutersJuly 13, 2016
Carl Icahn Recently Bought a ‘Large Position’ in Allergan
FinanceCarl Icahn Recently Bought a ‘Large Position’ in Allergan
By Sy MukherjeeMay 31, 2016
CNBC Events
FinanceAllergan Is Buying Back Up to $10 Billion in Stock
By Reuters and Fortune EditorsMay 10, 2016
Stocks Close Sharply Lower As Oil Prices Continue Decline
FinanceThese Biopharma Companies Are the World’s Top Shareholder Value Creators
By Sy MukherjeeMay 3, 2016
The CEO of Valeant Pharmaceuticals has suggested that Allergan is fat, overstaffed and ripe for big
HealthAllergan Struck a $3.3 Billion Alzheimer’s Drug Deal Right After Its Pfizer Merger Collapsed
By Sy MukherjeeApril 7, 2016
Pfizer In Merger Talks With Allergan PLC
HealthPfizer and Allergan Scrap $160 Billion Deal
By ReutersApril 6, 2016
Pfizer In Merger Talks With Allergan PLC
FinancePfizer, Allergan to Mutually Terminate Merger
By ReutersApril 5, 2016
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
FinanceWall Street Is Betting the Pfizer-Allergan Deal Won’t Happen
By Jen WiecznerApril 5, 2016
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
LeadershipHere’s Why Allergan Shares Are Tanking
By ReutersApril 5, 2016
Why Teva’s $40 Billion Deal for Allergan’s Generic Drugs Is Being Delayed
HealthWhy Teva’s $40 Billion Deal for Allergan’s Generic Drugs Is Being Delayed
By Sy MukherjeeMarch 16, 2016
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
FinanceHere’s How Much More Pfizer Could Save in Taxes With Allergan Deal
By Jen WiecznerFebruary 26, 2016
U.S. Multinationals in Puerto Rico
HealthEli Lilly Just Lost the Latest Round in its Patent Battle
By ReutersFebruary 12, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceBiotech Stocks Crashed and Nobody Knows Why
By Jen WiecznerJanuary 28, 2016
Inside Teva Pharmaceuticals Headquarters
HealthCelgene Settles U.S. Patent Litigation for Revlimid
By Reuters and Aaron TaskDecember 22, 2015
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
Finance2015 Is Now the Biggest Year Ever for M&A
By Chris MatthewsDecember 4, 2015
1
  • 1
  • 2
  • 3
  • 4
  • 5
6
Most Popular
Politics
'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuzplaceholder alt text
By Fortune EditorsApril 11, 2026
Future of Work
Palantir CEO says AI ‘will destroy’ humanities jobs but there will be ‘more than enough jobs’ for people with vocational trainingplaceholder alt text
By Fortune EditorsApril 11, 2026
Real Estate
The 'affordability economy' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Beltplaceholder alt text
By Fortune EditorsApril 11, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.